ImmunityBio, Inc. IBRX Proceeds from issuance of commercial paper and other short-term borrowings
Proceeds from issuance of commercial paper and other short-term borrowings at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromShortTermDebt.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s proceeds from issuance of commercial paper and other short-term borrowings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s proceeds from issuance of commercial paper and other short-term borrowings?
- ImmunityBio, Inc. (IBRX) reported proceeds from issuance of commercial paper and other short-term borrowings of $61K in Q1 2026.